CTOs on the Move

BIA Separations

www.monoliths.com

 
BIA Separations is a Wilmington, DE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.monoliths.com
  • 1000 N West St Ste 1200
    Wilmington, DE USA 19801
  • Phone: 888.520.4246

Executives

Name Title Contact Details

Similar Companies

IMV technologies USA

The IMV Technologies Group is a leader in the areas of animal and human assisted reproduction technologies and veterinary imaging. IMV Technologies provides customers with solutions for animal artificial insemination; its human division, Cryo Bio System, offers solutions for human assisted reproduction including human embryo vitrification, human sperm freezing and preservation and other assisted reproduction technologies. The IMV imaging business provides customers with veterinary imaging solutions.

Cereset

#Cereset is a wellness company that helps their clients relax their #brain to manage stress and achieve restful #sleep. šŸ§ šŸ’¤ Centers across the US & Europe.

Legacy Health System

Legacy Health System is an Oregon-based not-for-profit, tax-exempt corporation that includes five full-service hospitals and a children's hospital.

LogicBio

We are a genome editing company developing genetic medicines for the fight against rare pediatric diseases. GeneRideā„¢ is a promoterless and nuclease-free approach to gene insertion which may improve the safety profile of AAV based gene therapies With GeneRideā„¢, the therapeutic gene is site-specifically integrated into the genome allowing durable gene expression in dividing cells and mature tissues. Furthermore, therapeutic gene expression is regulated by the targeted locus so production can be limited to specific cell types.

GigaGen

GigaGen is advancing a pipeline of first-in-class biotherapeutics, including novel oncology antibody drug combinations and the world`s first recombinant polyclonal hyperimmune gammaglobulin. Behind our diverse and growing pipeline is a mission to bring forth a new generation of highly efficacious drugs, driven by an unparalleled understanding of immune dysregulation. Our proprietary antibody discovery technology quickly characterizes every cell in complex immune systems, powering our selection of drug targets, identification of drug candidates and preclinical assessment of efficacy.